+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study



Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study



Annals of Surgical Oncology 25(1): 271-279



Approximately 20% of melanoma patients harbor metastases in non-sentinel nodes (NSNs) after a positive sentinel node biopsy (SNB), and recent evidence questions the therapeutic benefit of completion lymph node dissection (CLND). We built a nomogram for prediction of NSN status in melanoma patients with positive SNB. Data on anthropometric and clinicopathological features of patients with cutaneous melanoma who underwent CLND after a positive SNB were collected from nine Italian centers. Multivariate logistic regression was utilized to identify predictors of NSN status in a training set, while model efficiency was validated in a validation set. Data were available for 1220 patients treated from 2000 through 2016. In the training set (n = 810), the risk of NSN involvement was higher when (1) the primary melanoma is thicker or (2) sited in the trunk/head and neck; (3) fewer nodes are excised and (4) more nodes are involved; and (5) the lymph node metastasis is larger or (6) is deeply located. The model showed high discrimination (area under the receiver operating characteristic curve 0.74, 95% confidence interval [CI] 0.70-0.79) and calibration (Brier score 0.16, 95% CI 0.15-0.17) performance in the validation set (n = 410). The nomogram including these six clinicopathological variables performed significantly better than five other previously published models in terms of both discrimination and calibration. Our nomogram could be useful for follow-up personalization in clinical practice, and for patient risk stratification while conducting clinical trials or analyzing their results.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060117174

Download citation: RISBibTeXText

PMID: 29067603

DOI: 10.1245/s10434-017-6143-5


Related references

The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. European Journal of Surgical Oncology 42(12): 1906-1913, 2016

Prediction of outcome and tumor status of the non-sentinel node in melanoma patients with a positive sentinel node. Laboratory Investigation 80(3): 61A, 2000

Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. European Journal of Surgical Oncology 34(1): 82-88, 2008

Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. Yearbook of Dermatology and Dermatologic Surgery 2009: 423-424, 2009

High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. European Journal of Cancer 42(3): 372-380, 2006

Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. Journal of Experimental and Clinical Cancer Research 26(1): 71-76, 2007

The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. European Journal of Cancer 50(1): 111-120, 2014

The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival. Melanoma Research 22(5): 386-391, 2012

Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes - Analysis and importance of sentinel node status. Journal of Investigative Dermatology 123(2), 2004

Sentinel node biopsy is more accurate than elective lymph node dissection in determining the regional node status of patients with cutaneous melanoma. Annals of Surgical Oncology 11(2 Suppl.): S122-S123, 2004

Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. Journal of Clinical Oncology 28(29): 4441-4449, 2010

Prognostic Role of Multiple Lymphatic Basin Drainage in Sentinel Lymph Node-Negative Trunk Melanoma Patients: A Multicenter Study from the Italian Melanoma Intergroup. Annals of Surgical Oncology 23(5): 1708-1715, 2016

Evaluation of incomplete sentinel node biopsy procedures and sentinel node positivity rates as surgical quality-assurance parameters in melanoma patients. Annals of Surgical Oncology 19(12): 3919-3925, 2012

Sentinel lymph node biopsy to stage patients with cutaneous melanoma at the National Cancer Institute of Naples. Results from 240 sentinel node biopsies. Tumori 88(3): S12-S13, 2002

Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. European Journal of Surgical Oncology 39(2): 179-184, 2013